REGULATED PRESS RELEASE published on 09/19/2024 at 18:00, 1 year 9 months ago Rapport semestriel 2024 Le conseil d'administration d'EXACOMPTA CLAIREFONTAINE révèle ses résultats au 1er semestre 2024 et ses perspectives. Analyse sectorielle et financière incluses Communication Financière Résultats Perspectives Exacompta Clairefontaine Endettement Financier
REGULATED PRESS RELEASE published on 04/26/2024 at 18:00, 2 years 1 month ago DPEF - Rapport annuel 2023
BRIEF published on 04/02/2024 at 18:05, 2 years 2 months ago EXACOMPTA CLAIREFONTAINE annonce de solides résultats financiers pour 2023 Résultats Financiers Dividende Hausse Des Revenus Exacompta Clairefontaine Marché De La Papeterie
BRIEF published on 04/02/2024 at 18:05, 2 years 2 months ago EXACOMPTA CLAIREFONTAINE Reports Strong Financial Results for 2023 Financial Results Revenue Growth Dividend Exacompta Clairefontaine Stationery Market
REGULATED PRESS RELEASE published on 04/02/2024 at 18:00, 2 years 2 months ago Financial statements - 31 december 2023 EXACOMPTA CLAIREFONTAINE reports 2023 financial results with €843.2M revenue and €72.1M operating income. Decline in paper demand in Europe observed. Outlook uncertain with pulp prices rising and energy costs increasing Financial Results Revenue Exacompta Clairefontaine Paper Demand Pulp Prices
BRIEF published on 03/28/2024 at 18:05, 2 years 2 months ago EXACOMPTA CLAIREFONTAINE presents its 2023 financial results and outlook 2023 Results Financial Perspective Exacompta Clairefontaine Paper Sector Stationery Market
BRIEF published on 03/28/2024 at 18:05, 2 years 2 months ago EXACOMPTA CLAIREFONTAINE présente ses résultats financiers 2023 et perspectives Résultats 2023 Perspective Financière Exacompta Clairefontaine Secteur Papier Marché Papeterie
REGULATED PRESS RELEASE published on 03/28/2024 at 18:00, 2 years 2 months ago Arrêté des comptes au 31 décembre 2023 et perspectives Le conseil d'administration d'EXACOMPTA CLAIREFONTAINE a arrêté les comptes au 31 décembre 2023. Analyse des résultats, informations sectorielles, conjoncture, perspectives et résultats financiers du groupe Résultats Financiers Dividende Perspectives Comptes Annuels Exacompta Clairefontaine
BRIEF published on 03/08/2024 at 18:05, 2 years 3 months ago Evolution des droits de vote et actions chez EXACOMPTA CLAIREFONTAINE en 2023 Droits De Vote Actions AMF Exacompta Clairefontaine Evolution 2023
Published on 06/26/2026 at 14:05, 56 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 1 hour 1 minute ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 2 hours 1 minute ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 2 hours 16 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 01:40, 13 hours 21 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/26/2026 at 14:00, 1 hour 1 minute ago Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 1 hour 1 minute ago Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 1 hour 29 minutes ago Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 1 hour 30 minutes ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 1 hour 31 minutes ago AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026
Published on 06/26/2026 at 07:00, 8 hours 1 minute ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 8 hours 1 minute ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
